摘要
目的探讨基于药物治疗管理(MTM)和欧洲药学监护联盟(PCNE)分类系统的持续性药学监护模式对2型糖尿病(T2DM)患者的影响。方法选择2022年1月至2022年5月在辽宁省健康产业集团铁煤总医院明确诊断为T2DM的80例患者作为研究对象,随机数字表法分为对照组和药学监护组,每组40例,对照组接受传统“医-护”医疗服务模式,药学监护组在传统治疗模式的基础上接受药学监护,比较两组患者疾病情况、药物治疗效果、药物依从性及糖化血红蛋白(HbA1c)达标情况。结果药学监护组住院期间发现治疗效果问题42个,治疗安全性问题7个,其他问题2个。发生原因主要包括药物用法用量不当、选药不适宜及疗程不当等。药物相关问题(DRPs)的干预包括患者层面(24个)和医生层面(27个),干预后38个接受并执行,6个接受并部分执行,7个不被接受,最终32个DRPs得到解决,9个部分解决,10个未解决。药学监护组患者出院后用药依从性明显改善,且HbA1c达标率明显高于对照组(7.50%(31/40)vs 55.56%(20/36),χ^(2)=6.998,P<0.05)。结论基于MTM和PCNE分类系统对T2DM患者开展持续性药学监护,可及时发现、评估并解决DRPs,从而提高患者出院后的用药依从性并帮助患者维持血糖稳定。
Objective To explore the effect of continuous pharmaceutical care model based on medication therapy management(MTM)and PCNE classification system on the patients with type 2 diabetes mellitus(T2DM).Methods A total of 80 patients with T2DM admitted to Tiemei General Hospital of Liaoning Health Industry Group from January 2022 to May 2022 were selected as the subjects and randomly divided into the control group and the pharmaceutical care group,with 40 in each group.The patients in the control group were treated with traditional medical service mode,while those in the pharmaceutical care group were given pharmaceutical care on the basis of the traditional treatment mode.The illness condition,therapeutic effect,drug compliance and target rate of HbAlc were determined and compared between the two groups.Results Totally 42 problems of treatment effect,7 problems of treatment safety and 2 other problems were found in the pharmaceutical care group during the hospital stay.The main causes included improper drug usage and dosage,inappropriate drug selection and improper course of treatment.The interventions to DRPs included 24 cases for patients and 27 for doctors.After the intervention,38 cases accepted and implemented,6 cases accepted and partially implemented,and 6 cases did not accept.Finally,32 DRPs were solved,9 partially solved and 10 unresolved.The compliance of the patients in the pharmaceutical care group was significantly improved after the discharge,and the compliance rate of HbA1c of the pharmaceutical care group was significantly higher than that of the control group(7.50%(31/40)vs 55.56%(20/36),χ^(2)=6.998,P<0.05).Conclusion Continuous pharmaceutical care carried out for the T2DM patients based on MTM and PCNE classification system can facilitate timely discovery,assessment and solution of DRPs so as to improve the compliance and maintain stable blood glucose of the patients after the discharge.
作者
李鸿录
于源
彭宇
周唯
Li Hong-lu;Yu Yuan;Peng Yu;Zhou Wei(Department of Pharmacy,Tiemei General Hospital of Liaoning Health Industry Group,Diaobingshan 112700,China)
出处
《中国药物应用与监测》
CAS
2024年第3期288-290,共3页
Chinese Journal of Drug Application and Monitoring
关键词
2型糖尿病
药学监护
药物治疗管理
欧洲药学监护联盟
药物相关问题
Type 2 diabetes mellitus
Pharmaceutical care
Medication therapy management
Pharmaceutical care network Europe
Drug-related problem
